Shaping tomorrow’s healthcare through AI-powered innovations

We’re an AI-driven precision medicine pioneer, dedicated to reshaping the future of diagnostics, drug discovery, and treatment. Data is our foundation; patient well-being is our guiding star.
Renovaro scientists collaborating with medical professionals on cancer diagnostics and treatment

What makes us unique?

Our global perspective, relentless innovation, collaborative spirit, and unwavering commitment to excellence fuel every breakthrough, ensuring we stay ahead of the curve in shaping the future of healthcare.
Approach
Approach

Excellence

We settle for nothing less than the extraordinary – driving each discovery to improve lives and reshape healthcare.

Collaboration

Synergy sparks progress. We unite scientists, clinicians, and engineers to push the frontiers of modern medicine.

Global Reach

We partner worldwide to accelerate breakthroughs, ensuring game-changing therapies reach every corner of the globe.

Where data meets discovery

Transforming complex datasets into life-saving insights, we bridge science and humanity for a healthier future.
Get in touch
Get in touch

Envisioning a Healthier Tomorrow

We believe in a world where technology targets cancer at its earliest stage.
Through early diagnosis and precision medicine, we move closer each day to the ultimate goal:
a future free of preventable cancer deaths.
84%
Accuracy in machine learning models
3Billion
Data points processed daily by our systems
60+
Patents filed in various 
AI technologies
42PB
Of data is stored in our systems
AI-powered liquid biopsy technology detecting cancer biomarkers for early diagnosis and screening

Innovation isn’t just an option, it’s our imperative

Healthcare providers using Renovaro AI platform for cancer screening, diagnosis, and treatment planningAI precision medicine platform analyzing patient genetic profiles for personalized cancer therapyRenovaro full-stack Bio-AI platform architecture supporting cancer and neurology care continuumRenovaro Bio-AI platform treating cancer and neurology patients with precision medicine solutionsRenovaro laboratory researchers analyzing cancer biomarkers using AI-powered diagnostic equipmentHealthcare providers implementing Renovaro's AI cancer detection platform in clinical settingsRenovaro company timeline showing growth from 2023 startup to AI precision medicine leader
Healthcare providers using Renovaro AI platform for cancer screening, diagnosis, and treatment planningAI precision medicine platform analyzing patient genetic profiles for personalized cancer therapyRenovaro full-stack Bio-AI platform architecture supporting cancer and neurology care continuumRenovaro Bio-AI platform treating cancer and neurology patients with precision medicine solutionsRenovaro laboratory researchers analyzing cancer biomarkers using AI-powered diagnostic equipmentHealthcare providers implementing Renovaro's AI cancer detection platform in clinical settingsRenovaro company timeline showing growth from 2023 startup to AI precision medicine leader

Sparked your interest?

Our services are tailored to empower businesses and industries with innovative solutions that are not just technologically advanced but also socially responsible and sustainable.
Get in touch
Get in touch

The Renovaro timeline

August 2023
Renovaro launches to develop cell,
gene, and immunotherapies
Renovaro begins as a therapeutics company specializing in the genetic modification of dendritic cells to fight cancer and immune-mediated diseases.
September 2023
GEDiCube identifies 10K
cancer-specific biomarkers
GEDiCube, an Amsterdam-based technology startup uses proprietary algorithms to identify 10K plus biomarkers spanning 13 cancer types.
February 2024
Merger between Renovaro
and GEDiCube
GEDiCube is officially acquired by Renovaro in a stock-for-stock acquisition; GEDiCube is rebranded as Renovaro Cube, and LA-based Renovaro is rebranded as Renovaro Biosciences.
December 2024
Renovaro receives LUMINA grant
Renovaro receives grant approval for LUMINA project to develop advanced minimal residual disease detection platform for lung cancer from the Eurostars funding program.
February 2025
Renovaro receives 15M
in equity committed
Renovaro fundraising results in 15M in equity to advance its AI-driven cancer diagnostics and therapeutic development programs.
April 2025
Renovaro merges with BioSymetrics
Renovaro acquires New York based BioSymetrics, a translational medicine company.

Management team
& board of directors

At Renovaro, we celebrate diversity in all its forms, understanding that varied perspectiveslead to more innovative solutions.
Team
Team

John Doe

Lead AI Solutions Architect

Emily Doe

Director of Machine Learning Operations

Emily Smith

Director of Machine Learning Operations

Ethan Doe

Head of AI Research and Development

Jane Wang

Director of Machine Learning Operations

John Doe

Head of AI Research and Development

John Johnson

Lead AI Solutions Architect

Sophia Doe

Director of Machine Learning Operations

Sophia Patel

Director of Machine Learning Operations

Alex Johnson

Lead AI Solutions Architect

Ethan Turner

Head of AI Research and Development

Emily Wang

Director of Machine Learning Operations